Gold prices steady ahead of Fed decision; weekly weakness noted
Liminatus Pharma Inc. (LIMN) announced its board of directors initiated a strategic review to explore forming a digital asset investment vehicle. The preclinical-stage biopharmaceutical company said the prospective subsidiary would operate independently of its core clinical pipeline and focus on digital asset allocation and blockchain-integrated financial structures.
The company said it anticipates targeting up to $500 million in potential capital formation through private placements, convertible instruments, equity lines and other structured financing tools, if the initiative proceeds. The proposed fundraising would be conducted in alignment with SEC regulations and exemptions.
No capital has been raised or committed, no agreements have been executed, and no third-party partnerships have been established, according to the company. The internal review remains subject to final board approval, regulatory compliance and market conditions.
Liminatus stated it is working with legal, financial and regulatory advisors to determine the optimal structure, governance and compliance framework for the proposed initiative. The company said it will provide further disclosures in accordance with SEC and Nasdaq reporting requirements.
The initiative represents a potential diversification of the company’s treasury strategy beyond its primary focus on developing targeted cancer immunotherapies. Liminatus develops immunotherapies for cancer patients and is advancing a pipeline of therapies targeting cancer antigens and tumor-specific immune responses.